Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Medeor Therapeutics

Medeor Therapeutics
2012 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$57M LATEST DEAL AMOUNT
5 INVESTORS
Description

Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 1875 South Grant Street
  • Suite 130
  • San Mateo, CA 94402
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Medeor Therapeutics’s full profile, request a free trial.

Medeor Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 27-Nov-2017 $57M 000.00 00000 Completed Clinical Trials - General
3. Early Stage VC (Series A) 16-Oct-2015 000 000.00 0000 Completed Clinical Trials - General
2. Early Stage VC 02-Oct-2013 $1.55M $2.55M 000.00 Completed Clinical Trials - General
1. Seed Round 11-Jan-2013 $1M $1M 000 Completed Clinical Trials - General
To view this company’s complete deal history including valuation and funding, request access »

Medeor Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series A 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Seed 1 1,291,667 $0.000100 8% $1.2 $1.2 1x $1.2 4.67%
Seed 1,000,000 $0.000100 8% $1 $1 1x $1 3.61%
To view this company’s complete Cap Table, request access »

Medeor Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
RA Capital Management Asset Manager Minority 000 0000 000000 0
Sofinnova Investments Venture Capital Minority 000 0000 000000 0
Vivo Capital Venture Capital Minority 000 0000 000000 0
WuXi Healthcare Ventures Corporate Venture Capital Minority 000 0000 000000 0

Medeor Therapeutics Executive Team (10)

Name Title Board
Seat
Contact
Info
Steven Deitcher MD Co-Founder, Chief Executive Officer, President and Board Member
Matthew Plunkett Ph.D Chief Financial and Business Officer
Samuel Strober MD Scientific Founder
Elizabeth Read MD Senior Vice President, Product Development
Iqbal Husain Ph.D Senior Vice President, Program Management

2 Former Executives

You’re viewing 5 of 10 executives. Get the full list »

Medeor Therapeutics Board Members (7)

Name Representing Role Since Contact
Info
Anand Mehra MD Sofinnova Investments Board Member 000 0000
Frank Kung Ph.D Vivo Capital Board Member 000 0000
Peter Kolchinsky Ph.D RA Capital Management Board Member 000 0000
Steven Deitcher MD Medeor Therapeutics Co-Founder, Chief Executive Officer, President and Board Member 000 0000
Wei Li Ph.D WuXi Healthcare Ventures Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »